Published in Clin Cancer Res on January 12, 2010
Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers. Gynecol Oncol (2010) 1.61
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst (2014) 1.24
Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells. Gynecol Oncol (2011) 0.82
Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer. Oncogene (2016) 0.78
In-depth LC-MS/MS analysis of the chicken ovarian cancer proteome reveals conserved and novel differentially regulated proteins in humans. Anal Bioanal Chem (2015) 0.78
Elevated Concentrations of SERPINE2/Protease Nexin-1 and Secretory Leukocyte Protease Inhibitor in the Serum of Patients with Papillary Thyroid Cancer. Dis Markers (2017) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med (2006) 13.63
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol (2009) 7.80
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta (2006) 7.33
Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem (1997) 5.51
Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer (2003) 4.96
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol (2008) 4.82
Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell (2002) 4.08
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst (2003) 3.77
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul (2006) 3.32
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res (2008) 2.64
Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res (2000) 2.43
Coordinately up-regulated genes in ovarian cancer. Cancer Res (2001) 1.93
SLPI and elafin: one glove, many fingers. Clin Sci (Lond) (2006) 1.84
A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Proc Natl Acad Sci U S A (1996) 1.45
Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol (1992) 1.33
Kinetics of the inhibition of leukocyte elastase by the bronchial inhibitor. Biochim Biophys Acta (1982) 1.31
Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor. Infect Immun (2005) 1.25
Human bronchial leucocyte proteinase inhibitor. Rapid isolation and kinetic analysis with human leucocyte proteinases. Biochem J (1985) 1.25
Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease. Cancer Res (2005) 1.20
Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc Natl Acad Sci U S A (2003) 1.19
Secretory leukocyte protease inhibitor in cancer development. Ann N Y Acad Sci (2004) 1.18
ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int J Cancer (2003) 1.15
In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase. Clin Cancer Res (2009) 1.09
Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis. Gynecol Oncol (2005) 1.05
In silico chromosomal clustering of genes displaying altered expression patterns in ovarian cancer. Cancer Genet Cytogenet (2005) 1.04
Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo. Cancer Sci (2009) 0.97
Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death. Int J Oncol (2005) 0.94
Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery. J Biol Chem (2001) 0.93
Acquisition of chemoresistance following discontinuous exposures to cisplatin is associated in ovarian carcinoma cells with progressive alteration of FAK, ERK and p38 activation in response to treatment. Gynecol Oncol (2006) 0.93
The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells. Carcinogenesis (2007) 0.92
Secretory leukocyte peptidase inhibitor and lung cancer. Cancer Sci (2008) 0.92
Differential regulation of secretory leukocyte protease inhibitor and elafin by progesterone. Biochem Biophys Res Commun (2003) 0.91
Inhibition of mast cell chymase by eglin c and antileukoprotease (HUSI-I). Indications for potential biological functions of these inhibitors. Biol Chem Hoppe Seyler (1986) 0.90
The secretory leukocyte protease inhibitor (SLPI) suppresses cancer cell invasion but promotes blood-borne metastasis via an invasion-independent pathway. J Pathol (2007) 0.88
Secretory leukoprotease inhibitor inhibits cell growth through apoptotic pathway on ovarian cancer. Oncol Rep (2008) 0.84
The expression of secretory leukocyte protease inhibitor (SLPI) in the fallopian tube: SLPI protects the acrosome reaction of sperm from inhibitory effects of elastase. Hum Reprod (2002) 0.80
Inhibition of human, ovine, and baboon neutrophil elastase with Eglin c and secretory leukocyte proteinase inhibitor. Biol Chem Hoppe Seyler (1992) 0.77
Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 16.38
Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst (2002) 4.50
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol (2008) 3.32
A low-fat vegan diet improves glycemic control and cardiovascular risk factors in a randomized clinical trial in individuals with type 2 diabetes. Diabetes Care (2006) 2.15
Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov (2002) 2.15
Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency. Int J Cancer (2008) 2.09
What's in the 'BAG'?--A functional domain analysis of the BAG-family proteins. Cancer Lett (2002) 1.69
Physical and mental health of homebound older adults: an overlooked population. J Am Geriatr Soc (2010) 1.69
CAIR-1/BAG-3 abrogates heat shock protein-70 chaperone complex-mediated protein degradation: accumulation of poly-ubiquitinated Hsp90 client proteins. J Biol Chem (2003) 1.67
Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. Int J Cancer (2008) 1.65
Repression of gene expression by unphosphorylated NF-kappaB p65 through epigenetic mechanisms. Genes Dev (2008) 1.64
A low-fat vegan diet and a conventional diabetes diet in the treatment of type 2 diabetes: a randomized, controlled, 74-wk clinical trial. Am J Clin Nutr (2009) 1.62
Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. Cancer (2008) 1.62
Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers. Gynecol Oncol (2010) 1.61
A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol (2011) 1.57
The utility of gestures in patients with chest discomfort. Am J Med (2007) 1.54
Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a Src-dependent fashion. Angiogenesis (2011) 1.53
Patient access to new cancer drugs in the United States and Australia. Value Health (2011) 1.50
Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide. J Toxicol Environ Health B Crit Rev (2007) 1.49
Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res (2010) 1.48
Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res (2009) 1.46
Effect of blood collection tubes on total triiodothyronine and other laboratory assays. Clin Chem (2004) 1.45
Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther (2006) 1.41
Changes in nutrient intake and dietary quality among participants with type 2 diabetes following a low-fat vegan diet or a conventional diabetes diet for 22 weeks. J Am Diet Assoc (2008) 1.38
Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther (2006) 1.37
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer (2007) 1.36
Intensive nutrition education with or without supplementary feeding improves the nutritional status of moderately-malnourished children in Bangladesh. J Health Popul Nutr (2005) 1.36
D2 dopamine receptor Taq1A polymorphism, body weight, and dietary intake in type 2 diabetes. Nutrition (2008) 1.35
Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer (2010) 1.35
Role of exosomes released by chronic myelogenous leukemia cells in angiogenesis. Int J Cancer (2011) 1.34
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther (2006) 1.33
Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer. Proteomics (2003) 1.33
Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics (2002) 1.31
Comparative effectiveness of ST-segment-elevation myocardial infarction regionalization strategies. Circ Cardiovasc Qual Outcomes (2010) 1.28
Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. Mol Cancer Ther (2008) 1.28
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res (2010) 1.23
The MAPK pathway across different malignancies: a new perspective. Cancer (2014) 1.22
Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. Mol Cancer Ther (2008) 1.22
Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. Hum Pathol (2004) 1.22
Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma. Cancer (2004) 1.22
Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol (2011) 1.20
Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clin Cancer Res (2010) 1.16
Cancer's deadly signature. Nat Genet (2003) 1.16
CAIR-1/BAG-3 modulates cell adhesion and migration by downregulating activity of focal adhesion proteins. Exp Cell Res (2006) 1.14
The empirical basis for determinations of medical futility. J Gen Intern Med (2010) 1.13
Intracellular survival and vascular cell-to-cell transmission of Porphyromonas gingivalis. BMC Microbiol (2008) 1.11
Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther (2007) 1.11
Targeted optical fluorescence imaging of human ovarian adenocarcinoma using a galactosyl serum albumin-conjugated fluorophore. Cancer Sci (2007) 1.09
Vegetarian and vegan diets in type 2 diabetes management. Nutr Rev (2009) 1.07
Little evidence of correlation between growth in health care spending and reduced mortality. Health Aff (Millwood) (2010) 1.06
The granulin-epithelin precursor: a putative new growth factor for ovarian cancer. Gynecol Oncol (2003) 1.05
The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer. Clin Cancer Res (2003) 1.04
BAG3 protein regulates cell survival in childhood acute lymphoblastic leukemia cells. Cancer Biol Ther (2003) 1.04
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Invest New Drugs (2012) 1.03
Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. Cancer Chemother Pharmacol (2007) 1.01
Caught in the middle: the role of Bag3 in disease. Biochem J (2009) 1.01
The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. J Transl Med (2007) 1.01
Estimation of lipid peroxidation induced by hydrogen peroxide in cultured human lymphocytes. Dose Response (2011) 1.00
Better therapeutic trials in ovarian cancer. J Natl Cancer Inst (2014) 1.00
Genomics and proteomics: application of novel technology to early detection and prevention of cancer. Cancer Detect Prev (2002) 1.00
Impact of zinc deficiency on vibrio cholerae enterotoxin-stimulated water and electrolyte transport in animal model. J Health Popul Nutr (2006) 0.98
Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. Clin Cancer Res (2006) 0.97
Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo. Cancer Sci (2009) 0.97
A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer (2007) 0.96
Tumor microenvironment: what can effusions teach us? Diagn Cytopathol (2005) 0.95
Core-shell hydrogel microcapsules for improved islets encapsulation. Adv Healthc Mater (2012) 0.95
The interferon-inducible p202a protein modulates NF-kappaB activity by inhibiting the binding to DNA of p50/p65 heterodimers and p65 homodimers while enhancing the binding of p50 homodimers. J Biol Chem (2003) 0.94
BAG-4/SODD and associated antiapoptotic proteins are linked to aggressiveness of epithelial ovarian cancer. Clin Cancer Res (2007) 0.94
Enhanced function of immuno-isolated islets in diabetes therapy by co-encapsulation with an anti-inflammatory drug. Biomaterials (2013) 0.94
Proteomics and biomarkers in clinical trials for drug development. J Proteomics (2011) 0.94
A low-fat vegan diet elicits greater macronutrient changes, but is comparable in adherence and acceptability, compared with a more conventional diabetes diet among individuals with type 2 diabetes. J Am Diet Assoc (2009) 0.94
The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells. Carcinogenesis (2007) 0.92
Proteomics in clinical trials and practice: present uses and future promise. Mol Cell Proteomics (2006) 0.92
State of the science in cervical cancer: where we are today and where we need to go. Cancer (2014) 0.91
Effects of carboxyamidotriazole on in vitro models of imatinib-resistant chronic myeloid leukemia. J Cell Physiol (2008) 0.90
Constitution and quantity of lysis buffer alters outcome of reverse phase protein microarrays. Proteomics (2007) 0.90
Genomic and phenotypic analysis reveals a key role for CCN1 (CYR61) in BAG3-modulated adhesion and invasion. J Pathol (2009) 0.90
Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma. Cancer (2005) 0.89
Cost-effectiveness in the contemporary management of critical limb ischemia with tissue loss. J Vasc Surg (2012) 0.89
Proteomic profiling in ovarian cancer. Int J Gynecol Cancer (2009) 0.89
Assessment of cell viability, lipid peroxidation and quantification of DNA fragmentation after the treatment of anticancerous drug mitomycin C and curcumin in cultured human blood lymphocytes. Exp Toxicol Pathol (2009) 0.89
The ongoing evolution of proteomics in malignancy. Drug Discov Today (2007) 0.88
Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice. Neurobiol Dis (2004) 0.88
L-asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancer. J Cell Mol Med (2012) 0.87
SELDI-TOF mass spectrometry for cancer biomarker discovery and serum proteomic diagnostics. Pharmacogenomics (2005) 0.87
Signal transduction targets in invasion. Clin Exp Metastasis (2002) 0.87
Cell adhesion in ovarian cancer. Cancer Treat Res (2009) 0.86
Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer. J Clin Oncol (2003) 0.86
Calcium as a molecular target in angiogenesis. Curr Pharm Des (2003) 0.86
Both protein activation and gene expression are involved in early vascular tube formation in vitro. Clin Cancer Res (2002) 0.86
Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis. Cancer Res (2005) 0.85
The anti-apoptotic activity of BAG3 is restricted by caspases and the proteasome. PLoS One (2009) 0.85
Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature. Curr Opin Oncol (2004) 0.85
Feasibility and safety of sequential research-related tumor core biopsies in clinical trials. Cancer (2012) 0.84
Proteomic approaches in colon cancer: promising tools for new cancer markers and drug target discovery. Clin Colorectal Cancer (2005) 0.84
Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome. Cancer (2011) 0.84
Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma. Int J Gynecol Pathol (2009) 0.83
Applying proteomics in clinical trials: assessing the potential and practical limitations in ovarian cancer. Am J Pharmacogenomics (2005) 0.83